Show simple item record

dc.contributor.authorIzquierdo, María Jesús .
dc.contributor.authorCavia Saiz, Mónica 
dc.contributor.authorMuñiz Rodríguez, Pilar 
dc.contributor.authorFrancisco, Angel LM de .
dc.contributor.authorArias, Manuel .
dc.contributor.authorSantos, Javier .
dc.contributor.authorAbaigar, Pedro .
dc.date.accessioned2014-05-16T11:54:01Z
dc.date.available2014-05-16T11:54:01Z
dc.date.issued2012-11
dc.identifier.issn1471-2369
dc.identifier.urihttp://hdl.handle.net/10259.4/2515
dc.description.abstractBackground: Treatment with selective vitamin D receptor activators such as paricalcitol have been shown to exert an anti-inflammatory effect in patients on hemodialysis, in addition to their action on mineral metabolism and independently of parathyroid hormone (PTH) levels. The objective of this study was to evaluate the additional antioxidant capacity of paricalcitol in a clinical setting. Methods: The study included 19 patients with renal disease on hemodialysis, of whom peripheral blood was obtained for analysis at baseline and three months after starting intravenous paricalcitol treatment. The following oxidizing and inflammatory markers were quantified: malondialdehyde (MDA), nitrites and carbonyl groups, indoleamine 2,3-dioxygenase (IDO), tumor necrosis factor alfa (TNF-α), interleukin-6 (IL-6), interleukin-18 (IL-18) and C-reactive protein (CRP). Of the antioxidants and anti-inflammatory markers, superoxide dismutase (SOD), catalase, reduced glutathione (GSH), thioredoxin, and interleukin-10 (IL-10) levels were obtained. Results: Baseline levels of oxidation markers MDA, nitric oxide and protein carbonyl groups significantly decreased after three months on paricalcitol treatment, while levels of GSH, thioredoxin, catalase and SOD activity significantly increased. After paricalcitol treatment, levels of the inflammatory markers CRP, TNF-α, IL-6 and IL-18 were significantly reduced in serum and the level of anti-inflammatory cytokine IL-10 was increased. Conclusions: In renal patients undergoing hemodialysis, paricalcitol treatment significantly reduces oxidative stress and inflammation, two well known factors leading to cardiovascular damagees
dc.description.abstractBackground: Treatment with selective vitamin D receptor activators such as paricalcitol have been shown to exert an anti-inflammatory effect in patients on hemodialysis, in addition to their action on mineral metabolism and independently of parathyroid hormone (PTH) levels. The objective of this study was to evaluate the additional antioxidant capacity of paricalcitol in a clinical setting. Methods: The study included 19 patients with renal disease on hemodialysis, of whom peripheral blood was obtained for analysis at baseline and three months after starting intravenous paricalcitol treatment. The following oxidizing and inflammatory markers were quantified: malondialdehyde (MDA), nitrites and carbonyl groups, indoleamine 2,3-dioxygenase (IDO), tumor necrosis factor alfa (TNF-α), interleukin-6 (IL-6), interleukin-18 (IL-18) and C-reactive protein (CRP). Of the antioxidants and anti-inflammatory markers, superoxide dismutase (SOD), catalase, reduced glutathione (GSH), thioredoxin, and interleukin-10 (IL-10) levels were obtained. Results: Baseline levels of oxidation markers MDA, nitric oxide and protein carbonyl groups significantly decreased after three months on paricalcitol treatment, while levels of GSH, thioredoxin, catalase and SOD activity significantly increased. After paricalcitol treatment, levels of the inflammatory markers CRP, TNF-α, IL-6 and IL-18 were significantly reduced in serum and the level of anti-inflammatory cytokine IL-10 was increased. Conclusions: In renal patients undergoing hemodialysis, paricalcitol treatment significantly reduces oxidative stress and inflammation, two well known factors leading to cardiovascular damage.
dc.format.mimetypeapplication/pdf
dc.language.isoenges
dc.publisherBioMed Centrales
dc.relation.ispartofBMC Nephrology, 2012, 13, 159es
dc.rights.urihttp://creativecommons.org/licenses/by/2.0
dc.subjectOxidative Stress
dc.subjectImmunomodulation
dc.subjectReceptors
dc.subjectCalcitrio
dc.subjectParicalcitol
dc.subject19-nor-1alpha
dc.subject25-dihydroxyvitamin D2
dc.subject.otherBioquímica
dc.subject.otherBiochemistry
dc.subject.otherBiología molecular
dc.subject.otherMolecular biology
dc.titleParicalcitol reduces oxidative stress and inflammation in hemodialysis patientsen
dc.typeArtículoes
dc.typeinfo:eu-repo/semantics/article
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.relation.publisherversionhttps://doi.org/10.1186/1471-2369-13-159
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersionen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record